Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
Author:
Funder
Ministry of Health
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/24/12/2990/16702026/mdt364.pdf
Reference28 articles.
1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2;Slamon;N Engl J Med,2001
2. Trastuzumab containing regimens for early breast cancer;Moja;Cochrane Database Syst Rev,2012
3. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2–positive operable breast cancer;Buzdar;J Clin Oncol,2005
4. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
5. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial;Baselga;Lancet,2012
Cited by 106 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations;World Journal of Surgical Oncology;2024-09-12
2. Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practice;Pathology and Oncology Research;2024-08-29
3. Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis;BMC Cancer;2024-07-22
4. Morphological and molecular changes of oestrogen receptor‐positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study;Histopathology;2024-06-07
5. Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer;CHINESE J CANCER RES;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3